Brian E. Lacy’s research while affiliated with Mayo Clinic and other places

... AHRI data and survey methodology have been described in multiple publications. 13,[15][16][17] The study protocol was reviewed by the Sterling Institutional Review Board and classified as exempt because responses were deidentified in accordance with 45 CFR §46. Participants electronically signed informed consent. ...

Reference:

Gout Flare Burden in the United States: A Multiyear Cross‐Sectional Survey Study

... 9 Seseorang dengan leaky gut mengeluh diare kronis, kembung, ketidaknyamanan di daerah perut, mual, masalah kulit seperti jerawat atau eksim dan nyeri sendi. 10 Berbagai marker penanda masih terus dilakukan penelitian. Beberapa marker yang telah diketahui antara lain penurunan eskpresi protein adesi zonulin dan okludin, peningkatan inflamasi dan penuruan bakteri Laktobasilus. ...

Reference:

“Leaky gut” mengawali terjadinya berbagai penyakit. Bagaimana dengan gambaran “healthy gut”? : Sebuah Tinjauan Pustaka

... AHRI data and survey methodology have been described in multiple publications. 13,[15][16][17] The study protocol was reviewed by the Sterling Institutional Review Board and classified as exempt because responses were deidentified in accordance with 45 CFR §46. Participants electronically signed informed consent. ...

Reference:

Gout Flare Burden in the United States: A Multiyear Cross‐Sectional Survey Study

... Recently, PAMORA, including naldemedine, has become part of clinical practice and is recommended for patients with OIC refractory to traditional laxative [11,12]. Several studies have demonstrated the effectiveness of PAMORA in treating OIC [26,27], but few studies have investigated the preventive effects of prophylactic laxatives on OIC. Ozaki et al. compared prophylactic naldemedine with prophylactic magnesium oxide in terms of the incidence of OIC. ...

Reference:

Efficacy of prophylactic laxatives against opioid-induced constipation: retrospective propensity score matching analysis

... On the other, the increased permeability at intestinal barrier associated with IBS (with some genetic association to IBS-D) may promote reactions to toxins, microbial excretory/secretory products or food allergens gaining access from lumen to mucosal intestinal compartments thus interacting with lymphocytes and mast cells [10,11]. In fact, tenapanor, an inhibitor of Sodium-Proton ex-changer NHE3 that promotes permeability restoration is currently approved for use in IBS-C [12]. In line with these facts, serotonin produced in the gut by Enterochromaffin Cells (ECCs) is a wellknown general regulator of membrane permeability [13]. ...

Reference:

Intestinal Parasites and Irritable Bowel Syndrome: A Double Jeopardy

... Chronic N/V syndrome and gastroparesis are usually treated with prokinetics. Domperidone and Metoclopramide are often used, but unfortunately, both drugs can have serious side effects and their long-term use is restricted [18]. Erythromycin stimulates contractions of the stomach and small intestine. ...

Reference:

Whole Gut Motility Patterns in Patients with Chronic Nausea and Vomiting

... It is important to exclude secondary causes of CC, evaluate the presence of comorbidities and, in some instances (i.e., in refractory cases), explore the underlying pathophysiological mechanisms in order to improve management and therapeutic appropriateness [7,23,24]. In recent years, several surveys have been published regarding the management of CC [2,8,[25][26][27][28]. These surveys were mainly directed at patients and addressed prevalence and risk factors [2,25,26] or treatment strategies [8,27,28] for patients with chronic constipation. ...

Reference:

The Diagnosis and Management of Chronic Constipation in Italy: Results from a Survey Conducted among Italian Gastroenterologists

... In contrast, the etiology of DGBI is less well defined and responses to gut-brain psychological therapy 5 and pharmacotherapy 6 are arguably more variable, partly due to the lack of objective biomarkers detectable using routine clinical evaluation, which could help guide management. 7 Indeed, the management of DGBI relies to a greater extent on the biopsychosocial model; uniform and streamlined care can challenge healthcare systems when biological, psychological and social interventions must be delivered in nuanced, balanced measures. 8 Treatment of DGBI is further complicated by the greater stigma that patients with such conditions face compared to those with organic gastrointestinal (GI) disease. ...

Reference:

Authors' Response to: Do not forget recommendations for transition to the adult world in esophageal atresia patients!

... Tenapanor also alleviated other abdominal symptoms experienced by patients with IBS-C such as bloating, discomfort, cramping, and fullness. 63 Consistent with tenapanor's action to increase water retention in the intestinal lumen and improve gastrointestinal motility, most treatment-emergent adverse events in the phase 3 studies were gastrointestinal in nature. The most common adverse event reported among tenapanor-treated patients was diarrhea (14.6% in T3MPO-1, 16.0% in T3MPO-2, and 11.1% in T3MPO-3) ( Table 2). ...

Reference:

An Overview of the Effects of Tenapanor on Visceral Hypersensitivity in the Treatment of Irritable Bowel Syndrome with Constipation

... Overall, the gastroenterologists who were most affected by burnout were women and younger members of the profession, and this occurred as a result of the stressors from both the change in work from the virus and its effect on home life and financial uncertainty. Both family and patients were seen for shorter periods, and care for patients was more complicated, involving increased administration that concomitantly expanded the litigiousness of the environment [51]. ...

Reference:

Burnout in Medical Specialists Redeployed to Emergency Care during the COVID-19 Pandemic